MUMBAI, India & NAPLES, Fla., June 17, 2026
Lupin Limited, a leading global pharmaceutical company, has announced the launch of Azilsartan Medoxomil Tablets, 40 mg and 80 mg, in the United States following approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA). The newly launched product is a bioequivalent version of Edarbi® (Azilsartan Medoxomil) and is indicated for the treatment of hypertension in adults, helping lower blood pressure and reduce the risk of cardiovascular complications. The launch represents another important milestone in Lupin’s growing U.S. generics portfolio and strengthens the company’s position in the highly competitive cardiovascular therapeutics market. Notably, Lupin has secured the status of exclusive first-to-file applicant, making it eligible for 180-day generic drug exclusivity, a strategic advantage that could provide significant commercial benefits during the product’s initial market introduction.
FDA Approval Strengthens Lupin’s U.S. Generics Portfolio
The approval and launch of Azilsartan Medoxomil Tablets further demonstrate Lupin’s commitment to expanding patient access to affordable, high-quality medicines across major therapeutic categories. As one of the largest generic pharmaceutical manufacturers globally, Lupin continues to leverage its research, development, and manufacturing capabilities to bring cost-effective treatment options to patients and healthcare providers. The company’s exclusive first-to-file status grants a valuable six-month market exclusivity period, enabling Lupin to establish a strong presence before additional generic competitors enter the market.
Industry analysts view such exclusivity opportunities as critical growth drivers for generic pharmaceutical companies, particularly in therapeutic areas with consistent patient demand and established clinical use. The latest launch also reflects Lupin’s ongoing strategy of targeting products with strong commercial potential and meaningful healthcare impact.
Addressing Hypertension Through Affordable Treatment Access
Advertisement
Hypertension remains one of the most prevalent chronic diseases worldwide and is a major risk factor for cardiovascular conditions including heart attack, stroke, kidney disease, and heart failure. Effective blood pressure management is essential for reducing long-term health complications and improving patient outcomes. Azilsartan Medoxomil, an angiotensin II receptor blocker (ARB), is widely prescribed to help lower blood pressure by relaxing blood vessels and improving blood flow. By introducing a generic equivalent of Edarbi®, Lupin aims to increase treatment accessibility while supporting healthcare cost reduction efforts.
The product recorded estimated annual U.S. sales of approximately USD 53.5 million for the reference listed drug during the twelve months ending April 2026, highlighting the continued demand for therapies used in hypertension management. The launch provides physicians, pharmacists, and patients with an additional treatment option while reinforcing the importance of generic medicines in improving healthcare affordability.
Expanding Global Pharmaceutical Leadership
Headquartered in Mumbai, India, Lupin has established itself as a global pharmaceutical leader with products distributed in more than 100 countries and a diversified portfolio that includes branded formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company maintains a particularly strong presence in the United States and India across therapeutic areas such as respiratory medicine, cardiovascular disease, diabetes, anti-infectives, gastrointestinal disorders, central nervous system conditions, and women’s health. Supported by a network of 15 manufacturing facilities, seven research centers, and more than 24,000 employees worldwide,
Lupin continues to invest in innovation and patient-centric healthcare solutions. The U.S. launch of Azilsartan Medoxomil Tablets further underscores the company’s commitment to improving access to essential medicines while strengthening its reputation as a trusted provider of high-quality pharmaceutical products. As demand for affordable cardiovascular treatments continues to grow, Lupin’s latest market entry positions the company for continued expansion within the global healthcare landscape.
Source: Lupin press release
